(Q43281607)

18 November 2017

title

Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate (English)

1 reference

18 November 2017

Mattias Sandström

1

1 reference

18 November 2017

Ulrike Garske

2

1 reference

18 November 2017

Dan Granberg

3

1 reference

18 November 2017

Anders Sundin

4

1 reference

18 November 2017

Hans Lundqvist

5

1 reference

18 November 2017

publication date

2 September 2009

1 reference

18 November 2017

number of pages

14

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

18 November 2017

volume

37

1 reference

18 November 2017

issue

2

1 reference

18 November 2017

page(s)

212-225

1 reference

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

18 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-009-1216-8

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

21 January 2018

1 reference

12 December 2020

End-stage renal disease after treatment with 90Y-DOTATOC.

1 reference

12 December 2020

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate

1 reference

12 December 2020

A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy

1 reference

12 December 2020

Modelling of metastatic cure after radionuclide therapy: Influence of tumor distribution, cross-irradiation, and variable activity concentration

1 reference

12 December 2020

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship

1 reference

12 December 2020

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

12 December 2020

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

12 December 2020

OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine

1 reference

12 December 2020

A technique for the absolute measurement of activity using a gamma camera and computer

1 reference

12 December 2020

Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy

1 reference

12 December 2020

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

1 reference

12 December 2020

Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.

1 reference

12 December 2020

Dosimetry in Peptide radionuclide receptor therapy: a review.

1 reference

12 December 2020

The role of hybrid SPECT-CT in oncology: current and emerging clinical applications

1 reference

12 December 2020

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

1 reference

12 December 2020

Targeted radionuclide therapy

1 reference

12 December 2020

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

1 reference

12 December 2020

3D absorbed dose calculations based on SPECT: evaluation for 111-In/90-Y therapy using Monte Carlo simulations.

1 reference

12 December 2020

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

1 reference

12 December 2020

10.1007/S00259-009-1216-8

Identifiers

DOI

1 reference

18 November 2017

1 reference